Synonym
Ibandronate sodium. trade names: Boniva in the USA Bondronat in Europe Bonviva in Asia and Bondrova in Pakistan.
IUPAC/Chemical Name
sodium hydrogen(1-hydroxy-3-(methyl(pentyl)amino)-1-phosphonopropyl)phosphonate
InChi Key
LXLBEOAZMZAZND-UHFFFAOYSA-M
InChi Code
InChI=1S/C9H23NO7P2.Na/c1-3-4-5-7-10(2)8-6-9(11,18(12,13)14)19(15,16)17;/h11H,3-8H2,1-2H3,(H2,12,13,14)(H2,15,16,17);/q;+1/p-1
SMILES Code
CCCCCN(CCC(P(O)(O)=O)(P(O)(O[Na])=O)O)C
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Ibandronate sodium inhibits farnesyl diphosphate synthase (IC50 = 20 nM). Ibandronate sodium is also a bone resorption inhibitor. It has been investigated for in vitro anti-tumor effects, such as apoptosis induction, inhibitor of cell growth, inhibition of invasive behavior, and inhibition of angiogenesis and for its in vivo role in various cancers including breast and prostate cancers.
Biological target:
Ibandronate Sodium is a highly potent nitrogen-containing bisphosphonate used for the treatment of osteoporosis.
In vitro activity:
In lines with western blot, the results of autophagy flux and TEM assay further confirmed that autophagy, occurred in Ang II + IBAN group, was higher than that in the untreated and Ang II or IBAN-treated groups (Fig. 2B, C). Therefore, these findings demonstrated that IBAN promoted autophagy in Ang II-treated HUVECs and human pulmonary microvascular endothelial cells (HPMECs).
Reference: Cell Death Discov. 2022 Apr 9;8(1):186. https://pubmed.ncbi.nlm.nih.gov/35397636/
In vivo activity:
Administration of IBN (ibandronate) at 1 μg/kg (IBN_1) was insufficient for the suppression of bone loss and morphological change in trabeculae; however, administration of 3 μg/kg (IBN_3) and 10 μg/kg (IBN_10) significantly suppressed the osteoporotic changes induced by estrogen deficiency.
Reference: Calcif Tissue Int. 2022 Jun;110(6):736-745. https://pubmed.ncbi.nlm.nih.gov/34989822/
Preparing Stock Solutions
The following data is based on the
product
molecular weight
341.21
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation protocol:
1. Han J, Yang J, Wang Q, Yin X, Sun Z, Huang C, Chen G, Zheng L, Jiang D. Ibandronate promotes autophagy by inhibiting Rac1-mTOR signaling pathway in vitro and in vivo. Cell Death Discov. 2022 Apr 9;8(1):186. doi: 10.1038/s41420-022-00995-6. PMID: 35397636; PMCID: PMC8994753.
2. Lotz EM, Cohen DJ, Ellis RA, Wayne JS, Schwartz Z, Boyan BD. Ibandronate Treatment Before and After Implant Insertion Impairs Osseointegration in Aged Rats with Ovariectomy Induced Osteoporosis. JBMR Plus. 2019 Mar 6;3(7):e10184. doi: 10.1002/jbm4.10184. PMID: 31372590; PMCID: PMC6659452.
3. Ishimoto T, Saito M, Ozasa R, Matsumoto Y, Nakano T. Ibandronate Suppresses Changes in Apatite Orientation and Young's Modulus Caused by Estrogen Deficiency in Rat Vertebrae. Calcif Tissue Int. 2022 Jun;110(6):736-745. doi: 10.1007/s00223-021-00940-2. Epub 2022 Jan 6. PMID: 34989822; PMCID: PMC9108105.
4. Takeda S, Sakai S, Tanaka K, Tomizawa H, Serizawa K, Yogo K, Urayama K, Hashimoto J, Endo K, Matsumoto Y. Intermittent Ibandronate Maintains Bone Mass, Bone Structure, and Biomechanical Strength of Trabecular and Cortical Bone After Discontinuation of Parathyroid Hormone Treatment in Ovariectomized Rats. Calcif Tissue Int. 2017 Jul;101(1):65-74. doi: 10.1007/s00223-017-0255-6. Epub 2017 Feb 28. PMID: 28246925; PMCID: PMC5486915.
In vitro protocol:
1. Han J, Yang J, Wang Q, Yin X, Sun Z, Huang C, Chen G, Zheng L, Jiang D. Ibandronate promotes autophagy by inhibiting Rac1-mTOR signaling pathway in vitro and in vivo. Cell Death Discov. 2022 Apr 9;8(1):186. doi: 10.1038/s41420-022-00995-6. PMID: 35397636; PMCID: PMC8994753.
2. Lotz EM, Cohen DJ, Ellis RA, Wayne JS, Schwartz Z, Boyan BD. Ibandronate Treatment Before and After Implant Insertion Impairs Osseointegration in Aged Rats with Ovariectomy Induced Osteoporosis. JBMR Plus. 2019 Mar 6;3(7):e10184. doi: 10.1002/jbm4.10184. PMID: 31372590; PMCID: PMC6659452.
In vivo protocol:
1. Ishimoto T, Saito M, Ozasa R, Matsumoto Y, Nakano T. Ibandronate Suppresses Changes in Apatite Orientation and Young's Modulus Caused by Estrogen Deficiency in Rat Vertebrae. Calcif Tissue Int. 2022 Jun;110(6):736-745. doi: 10.1007/s00223-021-00940-2. Epub 2022 Jan 6. PMID: 34989822; PMCID: PMC9108105.
2. Takeda S, Sakai S, Tanaka K, Tomizawa H, Serizawa K, Yogo K, Urayama K, Hashimoto J, Endo K, Matsumoto Y. Intermittent Ibandronate Maintains Bone Mass, Bone Structure, and Biomechanical Strength of Trabecular and Cortical Bone After Discontinuation of Parathyroid Hormone Treatment in Ovariectomized Rats. Calcif Tissue Int. 2017 Jul;101(1):65-74. doi: 10.1007/s00223-017-0255-6. Epub 2017 Feb 28. PMID: 28246925; PMCID: PMC5486915.
1: Inderjeeth CA, Glendenning P, Ratnagobal S, Inderjeeth DC, Ondhia C. Long-term efficacy, safety, and patient acceptability of ibandronate in the treatment of postmenopausal osteoporosis. Int J Womens Health. 2014 Dec 17;7:7-17. doi: 10.2147/IJWH.S73944. eCollection 2015. Review. PubMed PMID: 25565901; PubMed Central PMCID: PMC4274146.
2: Shiraishi A. [Pharmacological profile and clinical evidence in patients with primary osteoporosis treated with intravenous ibandronate]. Nihon Yakurigaku Zasshi. 2014 Jun;143(6):302-9. Review. Japanese. PubMed PMID: 24919557.
3: Sittig HB. Pathogenesis and bisphosphonate treatment of skeletal events and bone pain in metastatic cancer: focus on ibandronate. Onkologie. 2012;35(6):380-7. doi: 10.1159/000338947. Epub 2012 May 22. Review. PubMed PMID: 22722461.
4: Sewerynek E, Stuss M. [The role of i.v. ibandronate administration in osteoporosis therapy]. Endokrynol Pol. 2011;62 Suppl 2:9-18. Review. Polish. PubMed PMID: 22125017.
5: Lee YH, Song GG. Efficacy and safety of monthly 150 mg oral ibandronate in women with postmenopausal osteoporosis: a systematic review and meta-analysis of randomized controlled trials. Korean J Intern Med. 2011 Sep;26(3):340-7. doi: 10.3904/kjim.2011.26.3.340. Epub 2011 Sep 13. Review. PubMed PMID: 22016595; PubMed Central PMCID: PMC3192207.
6: Sewerynek E, Stuss M. The role of i.v. ibandronate administration in osteoporosis therapy. Endokrynol Pol. 2011 Jan-Feb;62(1):51-60. Review. PubMed PMID: 21365580.
7: Tobinai M. [Ibandronate]. Clin Calcium. 2011 Jan;21(1):79-86. doi: CliCa11017986. Review. Japanese. PubMed PMID: 21187598.
8: Weide R, Koppler H, Antras L, Smith M, Chang MP, Green J, Wintfeld N, Neary MP, Duh MS. Renal toxicity in patients with multiple myeloma receiving zoledronic acid vs. ibandronate: a retrospective medical records review. J Cancer Res Ther. 2010 Jan-Mar;6(1):31-5. doi: 10.4103/0973-1482.63570. Review. PubMed PMID: 20479544.
9: Lewiecki EM, Cooper C, Thompson E, Hartl F, Mehta D, Papapoulos SE. Ibandronate does not increase risk of atrial fibrillation in analysis of pivotal clinical trials. Int J Clin Pract. 2010 May;64(6):821-6. doi: 10.1111/j.1742-1241.2010.02335.x. Epub 2010 Mar 11. Review. PubMed PMID: 20337751.
10: Meattini I, Bruni A, Scotti V, Livi L, De Luca Cardillo C, Galardi A, Cipressi S, Biti G. Oral ibandronate in metastatic bone breast cancer: the Florence University experience and a review of the literature. J Chemother. 2010 Feb;22(1):58-62. Review. PubMed PMID: 20227995.
11: Morgan C, Wagstaff J. Is there a role for ibandronate in the treatment of prostate cancer patients with bony metastases? Acta Oncol. 2009;48(6):882-9. doi: 10.1080/02841860902874748. Review. PubMed PMID: 19925378.
12: Epstein S, Jeglitsch M, McCloskey E. Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg. Curr Med Res Opin. 2009 Dec;25(12):2951-60. doi: 10.1185/03007990903361307. Review. PubMed PMID: 19835464.
13: Amling M, Kurth A. Ibandronate: a review of its vertebral and nonvertebral antifracture efficacy. Womens Health (Lond Engl). 2009 Sep;5(5):467-73. doi: 10.2217/whe.09.38. Review. PubMed PMID: 19702445.
14: Rossini M, Viapiana O, Gatti D, Adami S. Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated review. Clin Ther. 2009 Jul;31(7):1497-510. doi: 10.1016/j.clinthera.2009.07.018. Review. PubMed PMID: 19695399.
15: Lakatos P. [Ibandronate in the treatment of postmenopausal osteoporosis]. Lege Artis Med. 2008 Oct;18(10):657-61. Review. Hungarian. PubMed PMID: 19227607.
16: Miller PD, Ward P, Pfister T, Leigh C, Body JJ. Renal tolerability of intermittent intravenous ibandronate treatment for patients with postmenopausal osteoporosis: a review. Clin Exp Rheumatol. 2008 Nov-Dec;26(6):1125-33. Review. PubMed PMID: 19210886.
17: Frampton JE, Perry CM. Ibandronate: a review of its use in the management of postmenopausal osteoporosis. Drugs. 2008;68(18):2683-707. doi: 10.2165/0003495-200868180-00011. Review. PubMed PMID: 19093707.
18: Emkey RD. Quarterly intravenous ibandronate for postmenopausal osteoporosis. Womens Health (Lond Engl). 2008 May;4(3):219-28. doi: 10.2217/17455057.4.3.219. Review. PubMed PMID: 19072470.
19: Bauss F, Bergström B. Preclinical and clinical efficacy of the bisphosphonate ibandronate in cancer treatment. Curr Clin Pharmacol. 2008 Jan;3(1):1-10. Review. PubMed PMID: 18690873.
20: Reginster JY, Neuprez A, Bruyère O. Ibandronate in profile: drug characteristics and clinical efficacy. Expert Opin Drug Metab Toxicol. 2008 Jul;4(7):941-51. doi: 10.1517/17425255.4.7.941 . Review. PubMed PMID: 18624681.
